Biogen (BIIB) Stock Forecast & Price Target

$229.41 +3.70 (+1.64%)

Closing price 04:00 PM Eastern

Extended Trading

$229.76 +0.34 (+0.15%)

As of 06:24 PM Eastern

Compare

Biogen - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 32 Analyst Ratings

Sell
1

Hold
12

Buy
19

Based on 32 Wall Street analysts who have issued ratings for Biogen in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 32 analysts, 1 has given a sell rating, 12 have given a hold rating, 18 have given a buy rating, and 1 has given a strong buy rating for BIIB.

Consensus Price Target

$236.04
2.89% Upside

According to the 32 analysts' twelve-month price targets for Biogen, the average price target is $236.04. The highest price target for BIIB is $300.00, while the lowest price target for BIIB is $175.00. The average price target represents a forecasted upside of 2.89% from the current price of $229.41.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for BIIB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Biogen and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BIIB Analyst Ratings Over Time

Type	Current Forecast 10/12/25 to 10/12/26	1 Month Ago 9/12/25 to 9/12/26	3 Months Ago 7/14/25 to 7/14/26	1 Year Ago 10/12/24 to 10/12/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	18 Buy rating(s)	18 Buy rating(s)	17 Buy rating(s)	11 Buy rating(s)
Hold	12 Hold rating(s)	13 Hold rating(s)	11 Hold rating(s)	17 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$236.04	$230.14	$220.04	$180.24
Forecasted Upside	2.89% Upside	5.98% Upside	14.63% Upside	22.97% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

BIIB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BIIB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Biogen Stock vs. The Competition

Type	Biogen	Healthcare Companies	Broader Market
Consensus Rating Score	2.59	2.32	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	0.24% Upside	947.83% Upside	19.32% Upside
News Sentiment Rating	Neutral News See Recent BIIB News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/12/2026	JPMorgan Chase & Co. 3 of 5 stars	Chris Schott 4 of 5 stars	Upgrade	Neutral ➝ Overweight	$210.00 ➝ $300.00	+32.91%
10/9/2026	UBS Group 4 of 5 stars	Michael Yee Not Rated	Boost Target	Buy	$240.00 ➝ $270.00	+21.70%
10/8/2026	Royal Bank Of Canada 3 of 5 stars	Brian Abrahams 5 of 5 stars	Lower Target	Outperform	$260.00 ➝ $256.00	+16.64%
9/24/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold (C-) ➝ Hold (C)
9/10/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Paul Matteis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$242.00	+12.68%
9/10/2026	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Morten Herholdt Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Reduce	$165.00 ➝ $175.00	-16.96%
9/3/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Amsellem Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$225.00 ➝ $245.00	+10.03%
8/13/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alexandria Hammond Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$300.00	+43.63%
8/4/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Salim Syed Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$221.00 ➝ $241.00	+16.11%
8/3/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Geoff Meacham Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$200.00 ➝ $215.00	+5.94%
My next big call (under $1) (Ad) The obvious way to "bet on Trump" in crypto is the Trump memecoin. And right now it's back in the news, with a contest offering its biggest holders a seat at dinner with the President. It's also about 97% below its peak. Because a memecoin doesn't benefit from good policy. It benefits from attention. The real winners of a pro-crypto Washington are the projects with actual businesses underneath them. Ones that get more valuable as rules get clearer, institutions get comfortable, and more money flows into the market. Here's my #1 pick for the Trump crypto era.
7/30/2026	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew Fein Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$237.00 ➝ $251.00	+22.25%
7/30/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sumant Kulkarni Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$245.00 ➝ $248.00	+20.27%
7/30/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Harrison Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$222.00 ➝ $231.00	+11.56%
7/30/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Phil Nadeau Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$215.00 ➝ $225.00	+9.59%
7/30/2026	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Laura Chico Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$201.00 ➝ $215.00	+4.28%
7/29/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jay Olson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$300.00	+43.24%
7/29/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Emily Field Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$185.00 ➝ $200.00	-2.73%
7/28/2026	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong Sell ➝ Hold
7/21/2026	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yatin Suneja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$260.00 ➝ $280.00	+38.53%
7/21/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jason Zemansky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$217.00 ➝ $215.00	+7.53%
7/13/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
7/13/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Srikripa Devarakonda Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$190.00 ➝ $235.00	+18.00%
6/29/2026	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ami Fadia Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$255.00 ➝ $256.00	+18.50%
6/22/2026	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight
5/15/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Outperform
5/1/2026	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
4/30/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target		$180.00 ➝ $190.00	+0.57%
4/30/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target		$201.00 ➝ $200.00	+5.87%
4/24/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$231.00 ➝ $238.00	+29.08%
4/9/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold
2/9/2026	Tudor Pickering Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	William Pickering Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$201.00	-0.09%
2/8/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$190.00 ➝ $200.00	-0.59%
2/6/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Evan David Seigerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Market Perform	$165.00 ➝ $196.00	-2.82%
10/31/2025	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target		$255.00 ➝ $250.00	+67.10%
9/24/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
2/13/2025	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	George Farmer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Sector Outperform	$244.00 ➝ $224.00	+61.69%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 06:26 PM ET.

Should I Buy Biogen Stock? BIIB Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, October 7, 2026. Please send any questions or comments about these Biogen pros and cons to contact@marketbeat.com.

Biogen
Bull Case

Here are some ways that investors could benefit from investing in Biogen Inc.:

Biogen Inc. shares are currently trading at $222.15, a level that sits just below the recent 52-week high of $230.49, indicating strong recent momentum and investor confidence in the company's trajectory.
The company demonstrated strong fundamental performance in its most recent earnings report on July 29, 2026, where it reported earnings per share of $3.60, significantly beating the consensus estimate of $2.94, while also exceeding revenue expectations with $2.74 billion in sales.
Wall Street analysts maintain a positive outlook, with the current consensus rating standing at "Moderate Buy" and an average price target of $230.14, suggesting that many experts believe the stock still has room to grow from its current price.
Biogen Inc. has a low beta of 0.09, which measures the stock's volatility relative to the overall market, making it a potentially stable investment that may experience less dramatic price swings than the broader market during periods of economic uncertainty.
Institutional investors have shown continued interest in the company, with 87.93% of the stock owned by hedge funds and other institutional investors, reflecting a high level of professional confidence in the company's long-term business model and product pipeline.

Biogen
Bear Case

Investors should be bearish about investing in Biogen Inc. for these reasons:

The stock carries a high price-to-earnings ratio of 39.32, meaning investors are paying nearly 40 times the company's current earnings for each share, which may be considered expensive compared to other sectors or if future earnings growth does not accelerate.
Short interest in the stock has been increasing recently, with the number of shares shorted rising to 5,817,797 as of September 15, 2026, indicating that a growing number of traders are betting against the stock's future performance.
Biogen Inc. does not currently pay a dividend, as indicated by a dividend yield of 0.00%, which may be a drawback for income-focused investors who prefer regular cash payments in addition to potential capital appreciation.
The company's revenue growth has been modest, with the most recent quarter showing a year-over-year increase of only 3.4%, which may limit the pace of earnings expansion and put pressure on the high valuation multiples.
Recent news highlights potential risks in the biotechnology sector, with reports suggesting that AI models have predicted failures in similar drug trials, raising concerns about the high costs and uncertainties associated with Biogen Inc.'s ongoing research and development efforts.

BIIB Forecast - Frequently Asked Questions

According to the research reports of 32 Wall Street equities research analysts, the average twelve-month stock price forecast for Biogen is $236.04, with a high forecast of $300.00 and a low forecast of $175.00.

32 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There is currently 1 sell rating, 12 hold ratings, 18 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BIIB shares.

According to analysts, Biogen's stock has a predicted upside of 2.89% based on their 12-month stock forecasts.

Over the previous 90 days, Biogen's stock had 4 upgrades and 1 downgrade by analysts.

Biogen has been rated by research analysts at Bank of America, Barclays, BMO Capital Markets, Canaccord Genuity Group, Citigroup, Guggenheim, HC Wainwright, HSBC, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Oppenheimer, Piper Sandler, Royal Bank Of Canada, Stifel Nicolaus, TD Cowen, UBS Group, Wedbush, Weiss Ratings, Wolfe Research, and Zacks Research in the past 90 days.

Analysts like Biogen more than other "healthcare" companies. The consensus rating for Biogen is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how BIIB compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Biogen Recommendations

MarketBeat monitors more than a dozen sources for Biogen analyst ratings, with the most recent rating issued on 10/12/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biogen (BIIB) Stock Forecast & Price Target

Biogen - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

BIIB Analyst Ratings Over Time

BIIB Analyst Recommendations By Month

BIIB Price Targets by Month

Biogen Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Biogen Stock? BIIB Pros and Cons Explained

Biogen
Bull Case

Biogen
Bear Case

BIIB Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Biogen Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biogen (BIIB) Stock Forecast & Price Target

Biogen - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

BIIB Analyst Ratings Over Time

BIIB Analyst Recommendations By Month

BIIB Price Targets by Month

Biogen Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Biogen Stock? BIIB Pros and Cons Explained

Biogen Bull Case

Biogen Bear Case

BIIB Forecast - Frequently Asked Questions

What is Biogen's forecast for 2026?

Should I buy or sell Biogen stock right now?

Does Biogen's stock price have much upside?

Has Biogen been upgraded or downgraded by Wall Street analysts recently?

What analysts cover Biogen?

Do Wall Street analysts like Biogen more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Biogen Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Biogen
Bull Case

Biogen
Bear Case